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Abstract Caspase-9 is the protease that mediates the
intrinsic pathway of apoptosis, a type of cell death. Acti-
vation of caspase-9 is a multi-step process that requires
dATP or ATP and involves at least two proteins, cyto-
chrome c and Apaf-1. In this study, we mathematically
model caspase-9 activation by using a system of ordinary
differential equations (an ODE model) generated by a
systems biology tool Simpathica—a simulation and rea-
soning system, developed to study biological pathways.
A rudimentary version of ‘‘model checking’’ based on
comparing simulation data with that obtained from a
recombinant system of caspase-9 activation, provided
several new insights into regulation of this protease. The
model predicts that the activation begins with binding of
dATP to Apaf-1, which initiates the interaction between
Apaf-1 and cytochrome c, thus forming a complex that
oligomerizes into an active caspase-9 holoenzyme via a
linear binding model with cooperative interaction rather
than through network formation.
Keywords Model checking   Model comparison
and selection   Apoptosis   Apoptosome   Caspase-9  
ODE model   Computational systems biology
Introduction
Systems biology aims to understand the fundamental
principles governing biological systems within a mathe-
matical framework. There are many advantages to using a
mathematical framework—the most important being that it
would then be relatively easy to translate biological sys-
tems into in silico models that can be manipulated
computationally and symbolically in a manner that is often
simply impossible with any in vitro or in vivo models.
Furthermore, it opens up the opportunities to adapt many
algorithmic and analysis techniques originally devised to
study natural or engineered dynamical systems that are
often represented as discrete, continuous or hybrid models
and analyzed using classical or modal logical frameworks.
In engineering sciences, such a consilience of model
building and model checking approaches has resulted in
robust and well validated engineered systems despite the
fact that their design could often evolve uncontrollably in
complexity to become too incomprehensible too quickly
(e.g., internet or power-grid), even to the team of engineers
who may have originally designed the system. But the
biological systems bring up even further obstacles—often
we do not know all the components participating in the
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DOI 10.1007/s11693-009-9022-yprocess, nor possess the absolute knowledge of all the
underlying interactions, complete with their kinetic
parameters. To overcome these obstacles, it is important to
develop system tools capable of establishing models with
symbolic and logical-inference methods, analyzing them by
mathematical approaches, evaluating the models with
numerical simulations, and suggesting the best model sys-
tem that recapitulates the biological system of interest.
Recently, our group developed an automated software
platform, dubbed Simpathica Model Checker, which pro-
vides ‘‘in one package’’ a set of the necessary systems
biology tools to carry out studies of enzymatic metabolic
pathways (Mishra et al. 2005). In this study we showcase an
application of this platform to tease out from small number
of experimental data, many of the details of biochemical
processes that are thought to be occurring during apoptosis.
While the study, highlighted here, is arguably limited by the
data-size, it provides many insights on the nature of the
‘‘biological model checking’’ and the algorithmic features
that systems biology tools need to incorporate.
Apoptosis is a type of cell death that removes mal-
functioning or damaged cell (Evan and Littlewood 1998;
Riedl and Shi 2004). Accordingly, a failure of apoptosis
can contribute to diseases, such as cancer, while uncon-
trolled activation of the apoptotic machinery can cause
unwanted loss of cells such as that occurring in neurode-
generative diseases. Apoptosis is executed by two main
pathways, intrinsic, which responds primarily to intracel-
lular stress, such as caused by chemotherapy, or extrinsic,
which is activated by agonists of so-called death receptors
(Cain 2003). The proteins involved in these pathways have
been characterized, but it remains unclear how these pro-
teins interact to ensure that apoptosis is prevented until
needed but then executed quickly. It is likely, however, that
this regulation involves quantitative changes in concen-
trations and activities of these proteins.
Both pathways of apoptosis can be described as a net-
work that regulates activation of caspases, the proteases
that disassemble the cell. Caspases (cysteine aspartate-
speciﬁc proteases) is a family of proteins that form the
execution part of the apoptotic machinery. The extrinsic
pathway activates caspase-8, while intrinsic pathway acti-
vates caspase-9; either of these proteases can activate
caspase-3, which does most of cell disassembly by cleaving
a set of proteins. Caspase-9 functions as a holoenzyme, in
which this protease is a catalytic subunit that is regulated
by an oligomer of Apaf-1, also known as the apoptosome
(Jiang and Wang 2004). Apaf-1 is a 130-kDa constitutively
expressed protein that includes a caspase recruitment
domain (CARD), a nucleotide-binding domain and 13 WD-
40 repeats (Zou et al. 1997, 1999). Apaf-1 is oligomerized
into the apoptosome following binding to cytochrome c in
a process that requires hydrolysis of ATP or dATP (Kim
et al. 2005; Yu et al. 2005). Because of experimental dif-
ﬁculties involved in studying the apoptosome activation, it
is uncertain what sequence of reactions leads exactly to
caspase-9 activation, or even how this protease is activated.
The modeling processes leading to caspase-9 activation
may help to learn how to regulate caspase-9 activation for
therapeutic purposes. In particular, the modeling approach
could predict the outcome in a perturbed system where the
balance between cell survival and cell death is compro-
mised. Modeling can also facilitate determination of
unknown factors involving the apoptotic pathway, and
provide a platform for exchanging knowledge and storing
information. Finally, a model of caspase-9 activation can
be eventually merged with other models modularly and
hierarchically to form a functional model of the cell.
Since Varner and colleagues proposed the ﬁrst mathe-
matical model of caspase activation (Fussenegger et al.
2000), several additional details have been proposed to
enhance mathematical models of apoptosis by combining
other major elements thought to be involved in apoptosis
(Legewie et al. 2006; Nakabayashi and Sasaki 2006; Stucki
and Simon 2005). For instance, there had existed earlier
models to provide frameworks analogous to ours, and
account for the various interactions that can affect apop-
tosis; however, the present study attempts to go much
further in ﬁlling in many details of the intrinsic pathway
that needed a clearer and more detailed description.
Moreover, there exists practically no study of mathematical
modeling of detailed apoptosome formation with the sole
exception being the work due to Nakabayashi and Sasaki
(Nakabayashi and Sasaki 2006). Even though Nakabayashi
and Sasaki had modeled apoptosome assembly with the
network interaction, here, in contrast to a purely simulation
study as theirs, we have aimed to combine model building
with model checking using novel recombinant experi-
mental data and automated systems biology tools.
Thispaperproposesamathematicalapproachtostudyand
evaluate models ofcaspase-9 activation; additionally, it also
highlightsourapproachtodesigningasoftwareplatformthat
can be used even by a novice user to apply, test, extend, or
modify such models. This platform is based on NYU’s
Simpathica Model Checker (SMC) that is part of the VALIS
softwareenvironment(Paxiaetal.2002).SMCwasdesigned
for modeling, simulation, and reasoning, and is capable of
effectivelymanipulatinglarge,complex,andhighlydetailed
biochemical systems (Mishra et al. 2005). Importantly,
Simpathica can generate all the necessary differential
equations starting from the user-deﬁned textual or graphical
descriptions, which allows even a user who is unfamiliar
with this mathematical approach to apply it effortlessly. In
thissystem,theonlyrequiredinputsarereasonablerangesof
initial concentrations of individual components and related
metabolic reactions with proper parameters (Mishra et al.
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1232005). Simpathica also allows users to modify an existing
model, modularly integrate with established or hypothetical
models,orsearch over afamilyofplausible models,through
a simple and efﬁcient Graphical user interface (GUI) using
multi-scriptingfacilitiesofVALIS.Insummary,Simpathica
allows users to construct and simulate models of metabolic,
regulatory, and signaling networks and then to analyze their
behavior with equal ease. By focusing on a well-studied and
almost completely characterized system such as intrinsic
apoptosis, we hope to better understand algorithmic issues
inherent to an SMC-like approach.
Below, we describe how Simpathica is used to model
the intrinsic apoptosis pathway as well as to check the
model by comparing model-based predictions with exper-
imental data.
Materials and methods
Recombinant system of caspase-9 activation
To study the biochemical mechanism of caspase activation,
we used a recombinant system with puriﬁed recombinants
Apaf-1, cytochrome c and procasepase-9 and-3 and
nucleotide. Caspase-3 activities were measured over a
duration, lasting 3 min because previous study had shown
that caspase 3 activities would increase linearly over a time
interval from 0 to 5 min (Rodriguez and Lazebnik 1999),
which was also supported by the simulation data that
exhibited an identical linear increment of caspase 3 activity
(Supplement Fig. 2). Note that, as a convenient reference
for the readers, all variables used in this study have been
summarized in the Supplement Table 1.
Apaf-1 and pro-caspase-9
All reagents for recombinant system were prepared as
described (Benedict et al. 2000; Fearnhead et al. 1998; Lin
2006; Rodriguez and Lazebnik 1999; Zou et al. 1999).
Assay for caspase-9 activity
We assessed caspase-9 activity by measuring conversion of
procaspase-3 to caspase-3. The assay was performed as
previously described elsewhere, using DEVD-AFC as a
ﬂuorogenic substrate (Rodriguez and Lazebnik 1999).
Brieﬂy,4 llofthetestedsolutionwasadded to0.2 mlofthe
assaybuffer(50 mMPIPES,10%Glycerol,0.1 mMEDTA,
2 mM DTT, pH7.0) containing 40 lM ﬂuorescent substrate
DEVD-AFC (Biomol, Inc). The ﬂuorescence released by
caspase-3 was measured at 37 C using a Cytoﬂuor 4000
plate reader, and the reaction rates were calculated from the
ﬂuorescence obtained before the saturation.
Assay for cytochrome c concentration
The ELISA was performed using human cytochrome c
immunoassay kit (Quantikine, DCTC0 from R&D sys-
tems). Brieﬂy, 1:1 series diluted of the reconstituted
cytochrome c standard (between 0 and 20 ng/ml) and
100 ll 293 cell extract (Rodriguez and Lazebnik 1999)
were transferred to polystyrene microplate coated with
monoclonal antibody against cytochrome c and incubated
for 2 h at room temperature. After aspiration and rinse with
wash buffer, 0.2 ml of the cytochrome c conjugate was
added to each well and incubated for 2 h at room tem-
perature. After ﬁnal wash, 0.2 ml of the substrate solution
was added to each well and incubated for half hour in the
dark. The development was stopped by adding 50 llo f
stop solution and the absorbance was compared and used to
calculate the concentration of cytochrome c.
Simulation program, Simpathica
The model equations and a graphical user interface (GUI)
were generated, using Simpathica Model Checker (devel-
oped by NYU Bioinformatics Group, New York University,
NY). This program is publicly available at NYU Bioin-
formatics Group website: http://bioinformatics.nyu.edu/
Software/index.shtml.
Theoretical basis for simulation
Simpathica is an advanced integrated systems biology tool
for simulating and reasoning about biological processes
(Mishra et al. 2005). Simpathica is able to model large,
modular and hierarchical biochemical pathways without
making overly simplifying assumptions. For instance, at
the lowest level, Simpathica may model a typical metabolic
reaction modulated by an enzyme using a classical sub-
strate-enzyme reaction. The key parameters, in Simpathica,
involving a Michaelis-Menten-like enzyme-modulated
reaction would be the three constants k1,k -1 and k2
(Reaction Constants).
Substrate1 þ Enzyme
  !
k1
  
k 1
Intermediate !
k2 Product
Simpathica follows a modular scheme, much as in S-sys-
tem (Voit 1991, 2000), to provide in a convenient manner a
description of a biochemical pathway as a composition of
several primitive reaction modules, which can be auto-
matically translated into a set of ODE’s with additional
algebraic constraints. Simpathica and XS-system (an
extension of the basic S-System, (Antoniotti et al. 2002,
2003a, b)) retains this modular structure while allowing for
a far richer set of modules and constraints. The Simpathica
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ancillary ones. The ﬁrst main module is a graphical front
end that is used to construct and simulate the networks
of ODE’s that are part of the model being analyzed.
Simpathica uses, among others, the SBML format (System
Biology Markup Language, http://www.sbml.org) for
exchanging model descriptions. The second module,
XSSYS is an analysis module based on a branching time
temporal logic that can be used in formulating questions
about the behavior of a system, represented as a set of
traces (time course data) obtained from wet-lab experi-
ments or computer simulations.
Comparison of simulation model predictions against
experimental data
In this study, our model checking approach consisted of
numerical comparison between simulation (in silico) data,
=SðU;TÞ, and experimental (in vitro) data, =0
VðU;TÞ,
leading to a better characterization of correct apoptosis
model. Based on this initial ODE model, a suitable Kripke
structure can be created to check more complex modal
logic queries within Simpathica (data not shown).
In general, we may assume that we use an in silico
model, expressed by a system of ODE’s
dx
dt
¼ fx ;u;t ðÞ and y ¼ gx ðÞ ð 1Þ
where u characterizes the input values, y the output values
and x, all other state variables. Thus, the input–output
behavior may be expressed as
y ¼= S u;t ðÞ ð 2Þ
Similarly, the input–output behavior observed in the in
vitro experiment is expressed as
y ¼= 0
V u;t ðÞ ¼ = V u;t ðÞ þ e; e N0 ;r2   
ð3Þ
The degree of similarities between simulated and
experimental results can be measured by two functions
EU(T) and ET(U), as follows
_ EU T ðÞ ¼
X N
i¼1
Yi  = S U;xi ðÞ ðÞ
2=N ð4Þ
and
_ ET U ðÞ ¼
X N
j¼1
Yj  = S xj;T
      2=N ð5Þ
where
Yi ¼= 0
V U;xi ðÞ ¼ = V U;xi ðÞ þ e ð6Þ
and
Yj ¼= 0
V xj;T
  
¼= V xj;T
  
þ e ð7Þ
Note that
Eð _ EUÞ¼
X N
i¼1
=V U;x ðÞ i =S U;xi ðÞ
   2=N þ r2 ð8Þ
and
E _ ET
  
¼
X N
j¼1
=V xj;T
  
 = S xj;T
      2=N þ r2 ð9Þ
Also note that, a continuous stochastic representation for
EU and ET can be given as
EU ¼
1
T
Zt
0
=V u;t ðÞ   = S u;t ðÞ ðÞ
2dt þ r2
þ
2r
T
Zt
0
=V u;t ðÞ   = S u;t ðÞ ðÞ dwt ð10Þ
and
ET ¼
1
U
Zu
0
=V u;t ðÞ   = S u;t ðÞ ðÞ
2du þ r2
þ
2r
U
Zu
0
=V u;t ðÞ   = S u;t ðÞ ðÞ dwu ð11Þ
If =V u;t ðÞ ¼ = S u;t ðÞ , Vu and Vt, then
E _ EU
  
¼ E _ ET
  
¼ EU ¼ ET ¼ r2 ð12Þ
The mean square error (MSE) was used to measure the
goodness-of-ﬁt for comparing the model predictions to the
experimental data. In this case, the model yielding lower
MSE values was deemed to provide a better ﬁt.
Mathematical modeling and numerical methods
In mammalian caspase-9 pathway, the required components
are Apaf-1 (A), caspase-9 (C9), cytochrome c (C), dATP
(D), and caspase-3 (C3). The signaling networks regulate
these components as illustrated in Fig. 1. Based on the
traditional caspase-9 pathway model with a speciﬁc role for
multimeric holoenzyme complex, we developed a kinetic
model that was used to represent caspase-9 pathway. The
differential equations, variables and default parameters
used in this study are summarized in the Table 2.
Modeling APAF-1, dATP and cytochrome c
interactions
The ﬁrst event of intrinsic apoptotic pathway is the release
of cytochrome c from mitochondria after exposure to
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123apoptotic inducers. Apaf-1 molecule binds to cytochrome c
(C) and acts as the initiator for caspase activation (Cain
2003). We treat the binding of Apaf-1 and cytochrome c as
reversible and the formation of complex as irreversible
(Fig. 2a, c). All abbreviations for the apoptotic components
are listed in Table 2.
A þ C
 !
a1
  
a 1
~ A   C !
a2 AC ð13Þ
~ A   Cand AC denote the intermediate molecule and Apaf-
1:cytochrome c complex, respectively. Previous studies
have shown that Apaf-1 also binds and hydrolyzes
nucleotides such as dATP. In this reaction, cytochrome c
does not affect dATP binding or hydrolysis to Apaf-1 (Zou
et al. 1997). Our models treat the binding of dATP and
Apaf-1:cytochrome c as reversible and the formation of
complex as irreversible (Fig. 2a, c).
AC þ D
 !
b1
  
b 1
~ A ~ C   D !
b2 ACD or S1 ðÞ ð 14Þ
~ A ~ C   Dand ACD denote the intermediate molecule and
Apaf-1:cytochrome c:dATP complex (or Apaf-1
monomer), respectively. It is believed that cytochrome c
binds to Apaf-1 and dATP stabilizes the binding of
cytochrome c to Apaf-1 (Zou et al. 1999). Based on this
information, we proposed an alternative model that Apaf-1
molecule binds to dATP ﬁrst and thus, acts as the initiator
for caspase activation (Fig. 2b, d).
A þ D
 !
a0
1
  
a0
 1
~ A   D !
a0
2 AD ð15Þ
AD þ C
 !
b0
1
  
b0
 1
~ A ~ D   C !
b0
2 ADC or S1 ðÞ ð 16Þ
~ A ~ D   C and ADC denote the intermediate molecule and
Apaf-1:cytochrome c:dATP complex (or Apaf-1 mono-
mer), respectively. We treat the binding of Apaf-1 and
dATP as well as Apaf-1:dATP and cytochrome c as
reversible and the formation of complex as irreversible.
Modeling APAF-1 multimerization
It is known that both dATP and cytochrome c are required
for Apaf-1 multimerization. Cytochrome c promotes the
multimerization of Apaf-1 cytochrome c complex when the
dATP/ATP bound to Apaf-1 is being hydrolyzed (Zou et al.
1999). Previous studies suggest that at least seven Apaf-1
oligomers are involved, as experimentally detected and
isolated using gel ﬁltration chromatography (Zou et al.
1999). Furthermore, they also suggest that two Apaf-1
monomers form Apaf-1 dimer complex.
S1 þ S1
 !
c11
  
r1 1
~ S1   ~ S1  !
r12 S1   S1 or S2 ðÞ ð 17Þ
~ S1   ~ S1 and S2 denote the intermediate molecule and Apaf-
1:cytochrome c:dATP dimer complex, respectively. We
Fig. 1 Caspase-3 activation as
described by a conventional
diagram (a) and in Simpathica
(b). Dashed line indicates
enzymatic reactions. In
Simpathica models, each step
has its own rate constants, kp
and p indicate reactions
parameters, e.g., k1, k-1 or k2
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123Fig. 2 Two models of initiation
of caspase-9 activation and
measurement of Caspase-3
activities using recombinant
system and comparison with
simulation data from two
apoptosis initiation models.
(a) and (b) are the schematic
diagrams, in which the ﬁrst
binding molecule is Apaf-1 and
(c) and (d) are the diagrams
generated by the simulation
program, Simpathica. We use
notation 1009 to indicate that
rate constant of the forward
reaction is increased by a scale
factor of 100 (unit is M
-1 s
-1);
similarly we denote by low
afﬁnity =10 nM
-1 s
-1 and high
afﬁnity =1000 nM
-1 s
-1. The
left panels are the corresponding
outputs from the model A (e and
g) and the right panels are the
corresponding graphs from the
model B (f and h). The top
panels are the corresponding
outputs from the simulation
with various concentration
ranges of cytochrome c (e and
f), and the bottom panels are the
corresponding graphs from the
simulation with various
concentration ranges of Apaf-1
(g and h). In recombinant
experiment, Caspase-3 activities
were measured at seven
different concentration of
cytochrome c, from 0 to
120 lM and Apaf-1, from 0 to
70 nM, after 3 min (lines with
closed circle). In simulations,
caspase-3 activities were
calculated at various
concentrations of cytochrome c
and Apaf-1 with two or three
different a2 (rate constant k2 in
step1), i.e., 2, 20, and 2000, as
well as with 10 different values
of a1 (rate constant k1 in step1)
from 0.1 to 1 at increment of
0.1. The other parameters are
listed in Supplement Table 1
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123treat the binding between Apaf-1 complexes as reversible
and the formation of complex as irreversible. Apaf-1 dimer
complex binds Apaf-1 monomer and forms Apaf-1 trimer
complex. Then, Apaf-1 dimer complex and Apaf-1
monomer form Apaf-1 trimer complex.
S2 þ S1
 !
r21
  
r2 1
~ S2   ~ S1  !
r22 S3 ð18Þ
~ S2   ~ S1 and S2 denote the intermediate molecule and Apaf-
1:cytochrome c:dATP trimer complex, respectively. We
treat the binding between Apaf-1 dimer complex and Apaf-
1 monomer reversible and the formation of complex as
irreversible. Then, Apaf-1 trimer complex and Apaf-1
monomer combine to form Apaf-1 tetramer complex.
Similar sets of equations hold for Apaf-1 pentamer,
hexamer, and heptamer complexes as shown below:
S3 þ S1
 !
r31
  
r3 1
~ S3   ~ S1  !
r32 S4 ð19Þ
S4 þ S1
 !
r41
  
r4 1
~ S4   ~ S1  !
r42 S5 ð20Þ
S5 þ S1
 !
r51
  
r5 1
~ S5   ~ S1  !
r52 S6 ð21Þ
S6 þ S1
 !
r61
  
r6 1
~ S6   ~ S1  !
r62 S7 ð22Þ
During the multimerization process, if there is a coopera-
tive interaction among Apaf-1 complexes, rate constants
of binding between complexes, nth-Apaf-1 complex bind-
ing rate, cn1 will continue to increase monotonically
(c21   c11, etc.). However, if there is no cooperative
interaction among Apaf-1 complexes, rate constants of
binding between complexes, cn1 will remain unaffected
(c21 = c11, etc.).
Modeling the formation and activation of holoenzyme
(or Apaf-1:cytochrome c:dATP:caspase-9 complex)
Based on previous studies, it is believed that the follow-
ing sequence of events occurs: Firstly, Caspase-9 interacts
with Apaf-1 only in the presence of dATP and cyto-
chrome c; secondly, Procaspase-9 only binds to the
multimeric holoenzyme complex; and ﬁnally, Apaf-1 and
procaspase-9 are present at an approximately 1:1 ratio in
the complex (Acehan et al. 2002; Zou et al. 1999). We
made a model for binding between Apaf-1 complex and
caspase-9. Apaf-1:cytochrome c:dATP:caspase-9 complex
is also known as a holoenzyme.
S7 þ P9
 !
d11
  
d1 1
~ S7   P9 !
d12 H1 ð23Þ
H1 þ P9
 !
d21
  
d2 1
~ H1   P9 !
d22 H2
H2 þ P9
 !
d31
  
d3 1
~ H2   P9 !
d32 H3
H3 þ P9
 !
d41
  
d4 1
~ H3   P9 !
d42 H4
H4 þ P9
 !
d51
  
d5 1
~ H4   P9 !
d52 H5
H5 þ P9
 !
d61
  
d6 1
~ H5   P9 !
d62 H6
H6 þ P9
 !
d71
  
d7 1
~ H6   P9 !
d72 H7 ¼ Hi
~ S7   P9 and H0 denote the intermediate molecule and
inactive holoenzyme, respectively. We treat the binding
between Apaf-1 heptamer complex and procaspase-9
reversible and the formation of complex as irreversible.
During the binding process, if there is a cooperative
interaction among procaspase-9, rate constants of binding
between complexes, nth-procaspase-9 binding rate, dn1
will be increased (d21   d11). However, if there is no
cooperative interaction among Apaf-1 complexes, rate
constants of binding between complexes, dn1 will remain
constant (d21 = d11). Procaspase-9 is rapidly autoactivated
once bound to multimeric Apaf-1 complex.
Hi  !
m1 Ha ð24Þ
Hi and Ha denote inactive holoenzyme (multimeric Apaf-1
complex with procaspase-9 or S7:P9) and active form
(multimeric Apaf-1 complex with caspase-9 or S7:C9),
respectively. We treat the conversion from inactive
holoenzyme to active form as irreversible. Caspase-9 is
fully active only when it is bound to Apaf-1 (Rodriguez
and Lazebnik 1999). The activated caspase-9 is released
from Apaf-1 complex.
Ha  !
w1 C9 þ S7 ð25Þ
It is assumed that new procaspase-9 has the ability to
occupy the empty space in the complex to be processed.
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Once Apaf-1 oligomer is formed, cytochrome c may not
be required for next reaction such as caspase-9 binding
and activation (Rodriguez and Lazebnik 1999). However,
cytochrome c is still detected in the functional caspase-
9-activating complex, which suggests that cytochrome c
may have additional role in this pathway (Zou et al.
1999). Therefore, we modeled possible dual roles of
cytochrome c in this study. First role is to bind Apaf-1
with dATP consistent with the assumptions of previous
studies (Eqs. 13, 14). Then, we assumed that cytochrome
c has another possible role, which involves activation of
holoenzyme, and incorporated this assumption into the
model.
Hi
  !
m1
C
Ha ð26Þ
C denotes cytochrome c. We treat the conversion from
inactive holoenzyme to active form as irreversible.
Modeling caspase-3 activation
Procaspase-3 is hydrolyzed by active Apaf-1 holoenzyme
complex (Ha).
P3
 !
v1
Ha
  
v 1
~ P3 !
v2 C3 ð27Þ
~ P3 and C3 denote intermediate molecule and caspase-3,
respectively. We treat the conversion of procaspase-3 into
the intermediate molecule as reversible and the formation
of active caspase-3, irreversible.
Modeling DEVD-Afc activity
DEVD-Afc is hydrolyzed by free caspase-3.
V
 !
Z1
C3
  
Z 1
~ V   !
Z2 F ð28Þ
~ V and F denote intermediate molecule and ﬂuorescent
molecule Afc, respectively. We treat the conversion of
DEVD-Afc into the intermediate molecule as reversible
and the formation of active caspase-3, irreversible. In this
study, we calculate Afc ‘‘rate’’ (fc/min) instead of free
‘‘Afc’’ concentration (nM).
The Robustness of the models
In this study, we have focused on estimating the relative
model robustness among several competing network
models, and used this to reconstruct the most plausible
model for a biochemical pathway. We believe that this
approach builds upon one of the best metrics for estimating
the reliability of computationally simulated models, espe-
cially in the context where one faces relatively small-
sample (and/or non-stationary) experimental data. We have
tested the robustness of the models, both extensively and
exhaustively, by varying the rate constant values, since
most metabolic reactions, e.g., those appearing in apoptosis
process, are primarily dependent on k1/k-1 ratios. In our
perturbation study, we conducted our parameter-sweep by
both increasing and decreasing k1 values and then simu-
lating the models for each case to evaluate the model
robustness.
Results and discussion
This study applied Simpathica, a novel systems biology
platform, to model and simulate the distal part of the
intrinsic pathway of apoptosis, which includes activation of
caspases-9 and 3. We also compared the results of simu-
lations to experimental data, which allowed us to optimize
the models and make some conclusions regarding mecha-
nisms of apoptosis.
Model derivation and parameter optimization
Our initial modeling is based on the current hypothesis of
intrinsic apoptosis (Jiang and Wang 2000; Kim et al. 2005;
Li et al. 1997; Rodriguez and Lazebnik 1999; Zheng and
Flavell 2000), which is initiated by the release of cyto-
chrome c from mitochondria (Jiang and Wang 2004). In
this model (Fig. 1a), the released cytochrome c binds Apaf-
1 monomer and the binding makes Apaf-1 active (step 1 in
Table 1 and Fig. 1a, Eq. 13). The active Apaf-1 then binds
to dATP and forms an oligomer, usually referred to as
apoptosome (step 2, Eq. 14). The oligomerization is sim-
pliﬁed in a classical enzyme reaction as reported
(Nakabayashi and Sasaki 2006, step 2) or in a series of
enzyme reactions (Eq. 17–22). The resulting apoptosome
recruits pro-caspase-9 to form the caspase-9 holoenzyme
(Eq. 23). The holoenzyme becomes active (Eq. 24, step 4)
and can catalyze the activation of caspase-3 (step 5), whose
activity is monitored by the increasing concentration of
processed peptide substrate DEVD-Afc (step 6). The active
holoenzyme can also dissociate into the apoptosome and
free processed caspase-9 (Eq. 25, step 7).
Since any modeling requires quantitative parameters of
modeled processes, we assembled published kinetic
parameters of processes involved in caspase-9 activation,
determined these parameters experimentally using an in
vitro or a recombinant system, or postulated them
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123(Table 1). We then compared the results of simulation with
the published experimental data (Rodriguez and Lazebnik
1999), and changed the kinetic constants used in the sim-
ulation to reconcile the differences between the simulated
and experimentally observed processes. We note that even
though we checked the models of apoptosis by adopting the
parameters from the literature, which were then validated
by recombinant systems, it still remained necessary to
check the robustness of the selected models, because model
parameters are known to depend on environmental condi-
tions such as buffer concentrations. To test the robustness
of the model, various ranges of all parameters were sim-
ulated in the model system and were used to calculate the
differences with experimental datasets by using serially
measured mean square errors (MSE). We observed that in
almost all cases parameter values selected from published
kinetic reactions led to excellent ﬁt with the most
‘‘plausible model,’’ i.e., the one characterized by the min-
imum MSE points (Supplement Fig. 1), thus indicating an
extremely low likelihood of overﬁtting.
Remarkably, changing most kinetic parameters in the
simulation, even by several orders of magnitude, had little
effect on caspase-3 activation. However, changing some
parameters, of critical signiﬁcance, within a relatively
narrow range signiﬁcantly changed the kinetics of active
caspase. Changing the Km and k2 of the active holoenzyme
(step 5) had the largest effect on caspase-3 activation
(Supplement Fig. 1f), suggesting that these parameters are
the key determinants of caspase-3 regulation. For example,
decreasing the Km of the active holoenzyme increases the
rate of pro-caspase-3 processing. On the other hand,
decreasing the dissociation rate constant of the active
holoenzyme (step 7) accelerates the cleavage and activation
of both caspase-3 and caspase-9 (Supplement Fig. 1e).
Table 1 The element reactions and kinetic parameters used in the simulation
Step Species or reactions
(equation number)
Values observed in experiments Values used in simulation
0 Nucleotide (dATP or D) [ATP] = 2–10 9 10
3 lM (Zubay 1993)
C D0 = 5000 nM
(Skoog and Bjursell 1974)
Cytochrome c (C) [CytC] = 1.1 9 10
-3 lM
E (i) C0 = 1200 nM
Determined in the 293 extract by cytochrome c ELISA kit
(R&D system).
Apaf-1 (A) [Apaf-1] = 1.5–3 nM (Fearnhead et al. 1998; Zou et al.
1997)
E
A0 = 4n M
Caspase-9 (C9) [Casp9] = 15–20 nM (Stennicke et al. 1999)
E P90 = 20 nM
Caspase-3 (C3) [Casp3] = 15–20 lM (Stennicke et al. 1998)
E P30 = 15 nM
Caspase-3 substrate (V) [DEVD-Afc] = 40 lM (Rodriguez and Lazebnik 1999)
E V0 = 40,000 nM
1C ? A ? AC (Eq. 13) kon = 10
7 M
-1 s
-1, koff = 10
-4 s
-1 (Purring et al. 1999)
R a1 = 1000 nM
-1 s
-1, a-1 = 2000 s
-1
KA = 4 9 10
7 M
-1 (Purring-Koch and McLendon 2000)
R a2 = 2s
-1
2A C ? D ? ACD (Eq. 14) KD = 1.72 9 10
-6 M (Jiang and Wang 2000)
R b1 = 1000 nM
-1 s
-1, b-1 = 1720 s
-1
b2 = 0.5 s
-1
2-1 ACD ? ACD ? 2ACD c1 = 50, c - 1 = 2000, c2 = 10
3 ACD ? P9 ? ACDP9
(Eq. 17–22)
Postulated, half of caspase-9 can be recruited in
holoenzyme in 5 min with the Ki[10,000 nM
(Inhibition of Caspase-9 by caspase-9 C285A)
(Ryan et al. 2002)
d1 = 140 nM
-1 s
-1, d-1 = 20,000 s
-1
d2 = 100 s
-1 (or 2 s
-1)
4 ACDP9 ? ACDC9 (Eq. 24) Postulated. 20nM of caspase-9 can be completely
cleaved in 20 min.
m1 = 3s
-1 (or 5 9 10
-1 s
-1)
5P 3      !
ACDC9 C3 (Eq. 27) KD = 1.08 9 10
-7 M (13)
R v1 = 6n M
-1 s
-1, v-1 = 1000 s
-1
Inhibition of Caspase-9 by peptide aldehydes
(Garcia-Calvo et al. 1998)
v2 = 20 s
-1
6V !
C3 F (Eq. 28) KM = 9 9 10
-6 M, k2 = 7.5 9 10
-1 s
-1(Moretti et al.
2002)
R
z1 = 5000 nM
-1 s
-1,
z-1 = 500,000 s
-1,z 2 = 90 s
-1
V0 = 40,000 nM (added in buffer)
7 ACDC9 ? ACD ? C9
(Eq. 25)
Postulated w1 = 0.5 s
-1
All abbreviations are listed in Table 2
C cell, E extract system, R recombinant system
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123Table 2 Differential equations,
variable deﬁnitions and default
parameters
Differential equations for Apaf-1, cytochrome c and dATP
_ AF ¼  a1   A0 ½  C0 ½  þ a 1 ~ A   C
  
_ CF ¼  a1   A0 ½  C0 ½  þ a 1 ~ A   C
  
_ DF ¼  b1   D0 ½  þ b 1 ~ A ~ C   D
  
_ ~ A   _ C
hi
¼þ a1   A0 ½  C0 ½    a 1 ~ A   C
  
  a2   ~ A   C
  
_ ~ A _ ~ C   _ D
hi
¼þ b1   AC ½  D0 ½    b 1 ~ A ~ C   D
  
  b2   ~ A ~ C   D
  
_ A _ C ¼þ a2   ~ A   C
  
  b1   AC ½  þ b 1   ~ A ~ C   D
  
_ A _ D ¼þ a0
2   ~ A   D
  
  b0
1   AD ½  þ b0
 1   ~ A ~ D   C
  
_ ~ A _ ~ D   _ C
hi
¼þ b0
1   AD ½  C0 ½    b0
 1 ~ A ~ D   C
  
  b0
2   ~ A ~ D   C
  
_ A _ C _ D ¼ _ S1 ¼ See differential equations for holoenzyme formation
Differential equations for heptametrical Apaf-1 complex formation
_ S1 ¼þ b2   ~ A ~ C   D
  
þ b0
2   ~ A ~ D   C
  
  c11   S1 ½  S1 ½  þ c1 1   ~ S1   ~ S1
  
_ ~ S1   _ ~ S1
hi
¼þ c11   S1 ½  S1 ½    c1 1   ~ S1   ~ S1
  
  c12   ~ S1   ~ S1
  
_ S2 ¼þ c12   ~ S1   ~ S1
  
  c21   S2 ½  S1 ½  þ c 1
2   ~ S2   ~ S1
  
_ ~ S2   _ ~ S1
hi
¼þ c21   S2 ½  S1 ½    c2 1   ~ S2   ~ S1
  
  c22   ~ S2   ~ S1
  
_ S3 ¼þ c22   ~ S2   ~ S1
  
  c31   S3 ½  S1 ½  þ c3 1   ~ S3   ~ S1
  
_ ~ S3   _ ~ S1
hi
¼þ c31   S3 ½  S1 ½    c3 1   ~ S3   ~ S1
  
  c32   ~ S3   ~ S1
  
_ S4 ¼þ c32   ~ S3   ~ S1
  
  c41   S4 ½  S1 ½  þ c4 1   ~ S4   ~ S1
  
_ ~ S4   _ ~ S1
hi
¼þ c41   S4 ½  S1 ½    c4 1   ~ S4   ~ S1
  
  c42   ~ S4   ~ S1
  
_ S5 ¼þ c42   ~ S4   ~ S1
  
  c51   S5 ½  S1 ½  þ c5 1   ~ S5   ~ S1
  
_ ~ S5   _ ~ S1
hi
¼þ c51   S5 ½  S1 ½    c5 1   ~ S5   ~ S1
  
  c52   ~ S5   ~ S1
  
_ S6 ¼þ c52   ~ S5   ~ S1
  
  c61   S6 ½  S1 ½  þ c6 1   ~ S6   ~ S1
  
_ ~ S6   _ ~ S1
hi
¼þ c61   S6 ½  S1 ½    c6 1   ~ S6   ~ S1
  
  c62   ~ S6   ~ S1
  
_ S7 ¼þ c62   ~ S6   ~ S1
  
  d11   S7 ½  P9 ½  þ d1 1   ~ S7   P9
  
Differential equations for holoenzyme formation
_ H1 ¼þ d12   ~ S7   P9
  
  d21 ~ H1
  
P9 ½  þ d2 1 ~ H1   P9
  
_ ~ H1   P9
hi
¼þ d21   H1 ½  P9 ½    d2 1   ~ H1   P9
  
  d22   ~ H1   P9
  
_ H2 ¼þ d22   ~ H1   P9
  
  d31 ~ H2
  
P9 ½  þ d3 1 ~ H2   P9
  
_ ~ H2   P9
hi
¼þ d31   H2 ½  P9 ½    d3 1   ~ H2   P9
  
  d32   ~ H2   P9
  
_ H3 ¼þ d32   ~ S2   P9
  
  d41 ~ H3
  
P9 ½  þ d4 1 ~ H3   P9
  
_ ~ H3   P9
hi
¼þ d41   H3 ½  P9 ½    d4 1   ~ H3   P9
  
  d42   ~ H3   P9
  
_ H4 ¼þ d42   ~ S3   P9
  
  d51 ~ H4
  
P9 ½  þ d5 1 ~ H4   P9
  
_ ~ H4   P9
hi
¼þ d51   H4 ½  P9 ½    d5 1   ~ H4   P9
  
  d52   ~ H4   P9
  
_ H5 ¼þ d52   ~ S4   P9
  
  d61 ~ H5
  
P9 ½  þ d6 1 ~ H5   P9
  
_ ~ H5   P9
hi
¼þ d61   H5 ½  P9 ½    d6 1   ~ H5   P9
  
  d62   ~ H5   P9
  
_ H6 ¼þ d62   ~ S5   P9
  
  d71 ~ H6
  
P9 ½  þ d7 1 ~ H6   P9
  
_ ~ H6   P9
hi
¼þ d71   H6 ½  P9 ½    d7 1   ~ H6   P9
  
  d72   ~ H6   P9
  
_ H7 ¼ _ Hi ¼þ d72   ~ H6   P9
  
  m1   Hi ½ 
_ Ha ¼þ m1   Hi ½    w1   Ha ½ 
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123Table 2 continued Differential equations for caspase-9
_ P9F ¼  d11   S7 ½  P9 ½  þ d1 1 ~ S7   P9
  
  d21   H1 ½  P9 ½  þ d2 1 ~ H1   P9
  
  d31   H2 ½  P9 ½  þ d3 1 ~ H2   P9
  
  d41   H3 ½  P9 ½  þ d4 1 ~ H3   P9
  
  d51   H4 ½  P9 ½  þ d5 1 ~ H4   P9
  
  d61   H5 ½  P9 ½  þ d6 1 ~ H5   P9
  
  d71   H6 ½  P9 ½  þ d7 1 ~ H6   P9
  
_ C9 ¼ w1   Ha ½ 
Differential equations for caspase-3
_ P3F ¼  v1   P30 ½  Ha ½  þ v 1 ~ P3   Ha
  
_ ~ P3   Ha
hi
¼þ v1   P30 ½  Ha ½    v 1 ~ P3   Ha
  
  v2 ~ P3   Ha
  
_ C3 ¼þ v2   ~ P3   Ha
  
Differential equations for DEVD-Afc
_ V ¼  z1   V0 ½  C3 ½    z 1 ~ V   C3
  
_ F ¼ z2   ~ V   C3
  
_ ~ V   C3
hi
¼þ z1   V0 ½  C3 ½    z 1 ~ V   C3
  
  z2 ~ V   C3
  
Variable deﬁnitions
Abbreviation Meaning
A Apaf-1 (AF, Free Apaf-1)
A0 Initial concentration of APAF-1
AF Free Apaf-1
D dATP (DF, Free dATP)
D0 Initial concentration of dATP
DF Free dATP
AD APAF-1:dATP complex
C Cytochrome c (CF, Free cytochrome c)
C0 Initial concentration of cytochrome c
CF Free cytochrome c
AC Apaf-1:cytochrome c complex
S1 (or (ADC)1) Apaf-1:dATP:cytochrome c complex (monomer)
S2 Apaf-1:dATP:cytochrome c complex (dimer)
S3 Apaf-1:dATP:cytochrome c complex (trimer)
S4 Apaf-1:dATP:cytochrome c complex (tetramer)
S5 Apaf-1:dATP:cytochrome c complex (pentamer)
S6 Apaf-1:dATP:cytochrome c complex (hexamer)
S7 Apaf-1:dATP:cytochrome c complex (heptamer)
P9 Procaspase-9 (P9F, Free procaspase-9)
P90 Initial concentration of procaspase-9
P9F Free procaspase-9
H1 Apaf-1:dATP:cytochrome c heptamer ? 1 procaspase-9
H2 Apaf-1:dATP:cytochrome c heptamer ? 2 procaspase-9
H3 Apaf-1:dATP:cytochrome c heptamer ? 3 procaspase-9
H4 Apaf-1:dATP:cytochrome c heptamer ? 4 procaspase-9
H5 Apaf-1:dATP:cytochrome c heptamer ? 5 procaspase-9
H6 Apaf-1:dATP:cytochrome c heptamer ? 6 procaspase-9
H7 (or Hi) Apaf-1:dATP:cytochrome c heptamer ? 7 procaspase-9
Hi Inactive holoenzyme (S7:7P9 complex)
Ha Active holoenzyme (S7:7C9 complex)
C9 Caspase-9 (C9F, Free and processed caspase-9)
P3 Procaspase-3 (P3F, Free procaspase-3)
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123Using the optimized simulation, we posed several spe-
ciﬁc questions regarding intrinsic apoptosis pathway.
1. Of the two molecules, cytochrome c or dATP,
which one initiates the formation of apoptosome?
The current model of Apaf-1 activation assumes that Apaf-
1 is bound to dATP, which is hydrolyzed upon binding of
Apaf-1 to cytochrome c. The resulting dADP remains
bound to the Apaf-1-cytochrome c complex and then is
exchanged by an undeﬁned mechanism for a molecule of
dATP, thus producing a complex that is oligomerized into
the apoptosome. Therefore, in this model the binding of
cytochrome c to Apaf-1 is the triggering event for the
formation of apoptosome and the consequent caspase-9
activation (Kim et al. 2005; Yu et al. 2005).
However, previous studies provided evidence that
cytochrome c binds Apaf-1 independently of the presence
of free dATP (Zou et al. 1997), that binding to cytochrome
c induces binding of Apaf-1 to dATP (Cain et al. 2000;
Jiang and Wang 2000), and that hydrolysis of dATP by
Apaf-1 is continuous and precedes binding of cytochrome c
(Zou et al. 1999). The possible discrepancies between these
observations and the model suggest that the exact sequence
of reactions that result in the active apoptosome is yet to be
established. We used our simulation to compare the effect
on caspase-9 and caspase-3 activation of two possible
initiating steps: binding of cytochrome c induces binding of
dATP (Fig. 2a), or binding of dATP induces binding of
cytochrome c (Fig. 2b).
Simulation of the ‘‘CytC-bind-ﬁrst’’ model showed no
signiﬁcant changes of caspase-3 activity in lower concen-
tration of both cytochrome c and Apaf-1 (Fig. 2e, g). To
test the robustness of the models, we also conducted
extensive perturbation analysis by simulating the model
with perturbed rate constants for the binding reaction of
cytochrome c with Apaf-1. In this model, decreased a1 also
causes no signiﬁcant changes of caspase-3 activity in lower
concentration of cytochrome c and Apaf-1 (Fig. 2e). This
result indicates that the formation of holoenzyme in this
model is relatively independent with respect to the con-
centration of cytochrome c and Apaf-1. Thus, any change
of cytochrome c and Apaf-1 concentration could not affect
the intrinsic apoptotic system, which contradicts the
experimental ﬁnding that elevation of cytochrome c indu-
ces apoptosis. However, the simulation of the second
model, ‘‘ATP-bind-ﬁrst’’ model, produced a stable increase
of caspase-3 activity at even lower concentration range of
cytochrome c and Apaf-1 regardless of changing rate
constants. This increased activity recapitulated the shape
assumed by the experimentally observed data in the
recombinant system (Fig. 2f, h). Therefore, the simulation
favored the model in which the ﬁrst step of apoptosome
formation is binding of dATP to Apaf-1—a process that
then facilitates subsequent binding of cytochrome c.
2. Does cytochrome c affect caspase-9 activation
after the apoptosome is formed?
Cytochrome c triggers oligomerization of Apaf-1, but is still
detected in the holoenzyme, which raises the following
question: Is this protein redundant in the apoptosome or
does it have some speciﬁc but as-yet unidentiﬁed functions?
Therefore, we compared two simulations. In one, cyto-
chrome c is involved only in the formation of Apaf-1
complex, while in the other cytochrome c is further assumed
to participate in holoenzyme activation, accompanied by
increasing reaction rate. We observed that there is detect-
able difference between the two models. Experimental data
showed that caspase-3 activity reaches its maximum value
at very small amount of cytochrome c (40 lM). Simulation
result clearly showed that if cytochrome c is involved in
holoenzyme activation, caspase-3 activity could not reach
itsmaximum valueateven highestconcentration (more than
120 lM) of cytochrome c (Fig. 3a, c). To test whether this
result correlates with other components, Afc production rate
is measured under a range of concentrations of Apaf-1
(Fig. 3d, e). This result is found consistent with the result
from previous simulation, and thus, prompting us to con-
clude that cytochrome c is unlikely to be involved in the
Table 2 continued P30 Initial concentration of procaspase-3
P3F Free procaspase-3
C3 Caspase-3 (C3F, Free and processed caspase-3)
V Free DEVD-Afc
V0 Initial concentration of DEVD-Afc
F Free ﬂuorescence molecule Afc
Default parameters
* For the cooperative binding of Apaf-1 complexes: c11 = 2, c21 = 4, c31 = 8, c41 = 16, c51 = 32,
c61 = 64 (units, M
-1s
-1)
** For the cooperative binding of procaspase-9: c11 = 20, c21 = 50, c31 = 80, c41 = 110, c51 = 140,
c61 = 170, c71 = 200 (units, M
-1s
-1)
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123caspase-9 activation. However, this analysis does not
exclude the possibility that cytochrome c in the complex
may still have a role in stabilizing the holoenzyme complex.
We further tested a seemingly plausible hypothesis that
slowing down the reaction rate could lead the simulation
study to a different conclusion, thus putting in doubt the
signiﬁcance of the single-role model. The simulation data
showed that reaction rate could be suitably slowed down in
the simulation to ﬁnd a rate that ﬁts the unfavorable dual-
role model the best, and brings it as close as possible to the
single-role model. Nonetheless, the mean square error test
continued to support the single-role model (Supplement
Fig. 3) over the best dual-role model.
3. Is there positive cooperative interaction during
the formation of Apaf-1 complex?
A key step in activation of caspase-9 is oligomerization of
Apaf-1. At present, how this oligomerization occurs is not
fully understood. The rapid rate of the oligomerization and
the number of the subunits in the oligomer suggests a
possibility of cooperative binding among the subunits.
Recently, Nakabayashi and Sasaki mathematically mod-
eled apoptosome assembly with a quadratic network
interaction framework that did not involve cooperative
binding (Nakabayashi and Sasaki 2006).
To test whether cooperative binding can also explain
how Apaf-1 is oligomerized, we simulated the effect of
cooperative binding on the activation of caspases-9 and -3,
we assumed that Apaf-1 oligomerization proceeds stepwise
(Eqs (17) through (22)). We created two simulation models
with a linear network interaction framework. In one of the
models, each Apaf-1 complex subunit has the same bind-
ing rate as previously bound subunits (c11 = c21 =
c31     = c71; cn1 is binding rate of nth Apaf-1 complex),
while in the other model the successive Apaf-1 complex
subunits have monotonically increasing binding rates
(c11   c21   c31     c71).
For comparison, we also simulated the Nakabayashi and
Sasaki’s complex network model (Nakabayashi and Sasaki
Fig. 3 Test to determine a second role of cytochrome c in intrinsic
apoptotic pathway besides the formation of Apaf-1 oligomer. The
Diagram shows the modeling pathway view in Simpathica (a). Bold
arrow in the diagram indicates that cytochrome c is involved in Apaf-1
complex formation. Broken arrow in the diagram indicates that
cytochrome c is also involved in another role, activating holoenzyme.
Two models, one assigning a single role (b and d) to cytochrome c and
the other assigning a dual role (c and e), were tested in two
components, cytochrome c (b and c) and Apaf-1 (d and e). The short
arrow in (b) indicates the concentration of cytochrome c (40 lM) at
which caspase-3 activity reaches the maximum activity in a graph
corresponding to the model in which cytochrome c is only involved in
the formation of Apaf-1 complex. The short arrow in (c) indicates the
concentration of cytochrome c (more than 120 lM) at which caspase-3
activity reaches its peak value in a graph corresponding to the model in
which cytochrome c has a dual role, controlling how Apaf-1 complex
(arrow with solid line in the left diagram) and enzymatic activity
facilitates holoenzyme activation (arrow with broken line in the left
diagram). Caspase-3 activities were measured at seven different
concentration of cytochrome c, from 0 to 120 lM after 3 min. The
complete set of parameters is listed in the Supplement Table 1
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1232006) in which each Apaf-1 monomer binding to the oli-
gomer has the same binding rate, but the monomers and
oligomers participate in complex network interactions. For
example, an Apaf-1 trimer can bind to a tetramer to form
the heptameric apoptosome, or bind to a dimer, to form an
intermediate pentamer, and so on. In this model, a total of
21 (=(7 9 6)/2) individual interactions would be necessary
to connect all components needed in the formation of a
heptamer (Fig. 4c).
In the linear model the increase of caspase-3 activity
was exponential at low rate constant and weakly sig-
moidal at higher rate constant if no positive cooperativity
was assumed (Fig. 4a), and sigmoidal if positive cooper-
ativity was introduced (Fig. 4b). The Nakabayashi and
Sasaki model produced a sigmoidal curve that was ini-
tially nearly linear (Fig. 4c). To determine which of the
curves ﬁts better the experimental results, we calculated
the mean square error (MSE, see Theoretical basis for
Simulation) between experimental and simulation data
using a least square distance function, and concluded that
the model based on a linear network with cooperative
interactions (Fig. 4b) ﬁts the data the best. We also tested
the robustness of the models by varying the binding rate
constants. As we expected, increased binding rates elevate
the holoenzyme activity. However, the resulting expo-
nential input–output curve at low rate constant remained
unchanged and overall shape remained more or less the
same. These simulation results indicate that modiﬁed
parameters do not change the patterns of the dynamics.
Therefore, we may reasonably conclude that there
exist positive cooperative interactions during the Apaf-1
complex formation.
Fig. 4 Cooperative binding of Apaf-1 can explain the rate of
caspase-3 activation. Top panel shows the modeling pathways view
in Simpathica and bottom panel shows the results from simulation and
in vitro experiment. a A linear network model with non-cooperative
interactions. b A linear network model with cooperative interactions.
c A complex network model with non-cooperative interactions.
Dashed lines indicate graphs from the recombinant experiment.
Caspase-3 activities were measured at seven different concentration
of Apaf-1, from 0 to 70 nM. Caspase-3 activities were calculated at
various concentration of Apaf-1 up to 70 nM (red lines). The
complete set of parameters is listed in Supplement Table 1
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1234. Is binding of procapase-9 to the apoptosome
cooperative?
Caspase-9 functions as a holoenzyme in which this protease
and Apaf-1 are present in 1:1 ratio (Acehan et al. 2002).
Thus, total of seven caspase-9 molecules can exist in holo-
enzyme complex even though it is not clear how this
oligomerization occurs. The simulation suggesting a posi-
tive cooperative binding among Apaf-1 complex subunits
(Fig. 4) led us to test whether binding of procaspase-9 to the
oligomer is also cooperative. We compared two alternative
models. In one model, each procaspase-9 molecule binds
with the same binding constant as the previous procaspase-9
during the formation of the holoenzyme (d11 = d21 =
d31     = d71; dn1 is binding rate of nth procaspase-9 mol-
ecule), while in the other alternative model the rate of
binding of each successive procaspase-9 molecules increa-
ses monotonically (d11   d21   d31 …   d71).
We found that assuming positive cooperative binding
of caspase-9 to the Apaf-1 oligomer could not by itself
explain the sigmoidal shape in the rate of caspase-3
activation observed experimentally (Fig. 5 left and right
panel). Moreover, positive cooperative binding of cas-
pase-9 to the Apaf-1 oligomer could accelerate the
holoenzyme activity in the higher concentration of Apaf-1
relative to the activity measured by the experimental data.
We also tested the robustness of the models by perturbing
binding rate constants. However, since the overall shape
remained the same, we concluded that caspase-3 activa-
tion involves positive cooperative interaction among
Apaf-1 molecules during the formation of Apaf-1 multi-
meric complex in low concentration of Apaf-1 (Fig. 5
bottom panel).
Based on the previous results, we proposed that seven
Apaf-1 complex subunits interact cooperatively with each
other while forming the apoptosome, and that this positive
Fig. 5 Comparison of cooperative interactions among procaspase-9
during the formation of holoenzyme complex and cooperative
interaction among Apaf-1 complex subunits during the formation
of Apaf-1 multimeric complex. Left panel exhibits an absence of
cooperative interaction among procaspase-9 during the formation of
holoenzyme complex. Right panel exhibits a cooperative interaction
among procaspase-9 during the formation of holoenzyme complex. d1
indicates rate constant for the binding of procaspase-9. Top panel
exhibits no cooperative interaction among Apaf-1 complex subunits
during the formation of Apaf-1 multimeric complex. Bottom panel
exhibits a cooperative interaction among Apaf-1 complex subunits
during the formation of Apaf-1 multimeric complex c1 (rate constant
k1 in step 2-1) indicates rate constant for the binding of Apaf-1
complex (unit of c and d is M
-1 s
-1). In all simulation, caspase-3
activities were calculated at various concentration of Apaf-1 up to
70 nM. Bold lines indicate graphs from the recombinant experiment.
Caspase-3 activities were measured at seven different concentration
of Apaf-1, from 0 to 70 nM. A complete list of parameters appears in
Supplement Table 1
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123cooperation can explain the rapidity of caspase-9 activation
during apoptosis, especially considering that assuming
positive cooperativity in the binding of caspase-9 to the
apoptosome failed to affect the rates of caspase-3 activation
5. Is free caspase-9 active?
The experimental evidence indicates that caspase-9 is fully
active only when it is bound to Apaf-1 (Rodriguez and
Fig. 6 Holoenzyme-bound caspase-9 is enough to activate caspase-3.
Panel (a) shows the schematic diagrams, which implicitly assume a
role only for holoenzyme-bound caspase-9 in activating caspase-3.
Panel (b) shows the schematic diagrams, which assume that both
holoenzyme bound caspase-9 and free caspase-9 jointly activate
caspase-3. Bottom panels (c to f) are the corresponding graphs from
the simulation with various concentration ranges of cytochrome c
(g and h) and Apaf-1 (e and f). The left panels (c and e) are the
outputs of the simulation model from panel A and the right panels (d
and f) are the outputs of a simulation model from panel B. In
recombinant experiment as well as simulation, caspase-3 activities
were measured at similar concentrations described in Fig. 2.A
complete list of parameters appears in Supplement Table 1
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123Lazebnik 1999; Stennicke et al. 1999), while earlier studies
suggested that processed caspase-9 can also be active (Cain
et al. 2000; Zou et al. 1999). We simulated these two pos-
sibilities (Fig. 6a, b) and found that the ﬁrst model ﬁts the
experimental ﬁndings better (Fig. 6c, e). Simulation study
shows that if free caspase-9 also has any activity, holoen-
zyme activity in high concentration of Apaf-1 should have
been much higher than what we observed in experiments.
Whenwecomparedtheactivityoffreecaspase-9againstthat
ofcomplex-boundcaspase-9s,weobservedthatholoenzyme
activity was increased by almost 50%, in higher concentra-
tionofApaf-1.However,ifweexaminetheactivitiesatalow
level of free or complex-bounded caspase-9s, we observed
both holoenzyme activities to be of similar magnitudes.
Therefore,weconcludedthatfreecaspase-9hasnoneorvery
little inﬂuence. Our simulation data conﬁrmed the result
from recent experimental data that caspase-9 is fully active
only when it is bound to Apaf-1 (Rodriguez and Lazebnik
1999), and that, in contradiction to earlier mathematical
models, the apoptotic process is maintained primarily by
caspase-3 or caspase-9 (Fussenegger et al. 2000; Legewie
et al. 2006; Stucki and Simon 2005).
Based on simulation data, we reconstructed the model for
the intrinsic apoptotic pathway (Fig. 7). Based on the anal-
ysis from this study, we concluded that the best target
molecule to control apoptosis is not necessarily initiator
caspase such as caspase-9 but a holoenzyme complex.
Althoughthebehaviorofcaspase-3activityismainlycaused
by positive cooperative binding of Apaf-1 subunits, coop-
erative binding of procaspase-9 still can affect caspase-3
activity in low concentration of Apaf-1. It is interesting that
the simulation data from this study based on positive coop-
erative interactions almost matched exactly with in vitro
experimental dataforalldatapoints.This resultsupportsthe
main claim of this study that all components and their
interactions used in this simulation study are structured
appropriately in their ability to use the experimental data to
distinguish among a family of plausible models.
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